

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **VIVA BIOTECH HOLDINGS**

### **维亚生物科技控股集团**

*(Incorporated in the Cayman Islands as an exempted company with limited liability)*

**(Stock code: 1873)**

## **PROPOSED CHANGE OF AUDITOR**

This announcement is made by Viva Biotech Holdings (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

### **Retirement of Deloitte**

The board of directors of the Company (the “**Board**”) announces that Deloitte Touche Tohmatsu (“**Deloitte**”) will retire as the auditor of the Company upon expiration of its current term of office at the conclusion of the forthcoming annual general meeting of the Company to be held on June 10, 2020 (the “**AGM**”). The Board and Deloitte has mutually agreed not to renew the appointment as they could not reach a consensus on the audit fee for carrying out the audit work for the year ending December 31, 2020.

Deloitte has confirmed that there are no matters in connection with its retirement that need to be brought to the attention of the shareholders (the “**Shareholders**”) and creditors (the “**Creditors**”) of the Company. The Board and the Audit Committee of the Company also confirms that there are no disagreements or unresolved matters between Deloitte and the Group, and there are no other matters in respect of the proposed change of auditor that need to be brought to the attention of the Shareholders and Creditors.

The Company would like to extend its sincere gratitude to Deloitte for its quality services provided to the Group in previous years.

## **Proposed Appointment of Ernst & Young**

The Board has resolved, with the recommendation of the Audit Committee of the Company, that Ernst & Young be proposed to be appointed as the auditor of the Company following the retirement of Deloitte with effect from the conclusion of the AGM and until the conclusion of the next annual general meeting of the Company, subject to the approval by the Shareholders at the AGM.

A circular containing, among other things, information in relation to the proposed change of auditor, together with the notice to convene the AGM, will be dispatched to the Shareholders in due course.

By order of the Board  
**Viva Biotech Holdings**  
**Mao Chen Cheney**  
*Chairman and Executive Director*

Hong Kong, May 7, 2020

*As at the date of this announcement, the Board comprises four Executive Directors, namely, Mr. Mao Chen Cheney (Chairman), Mr. Wu Ying, Mr. Hua Fengmao and Mr. Ren Delin; two Non-executive Directors, namely, Ms. Mao Jun and Ms. Sun Yanyan; and three Independent Non-executive Directors, namely, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.*